We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Wednesday, November 9th, Mylan will release its third quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.
Dave will look at Mylan’s past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Mylan ahead of earnings.
Mylan in Focus
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Mylan is expected to report earnings at $1.51 a share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 0.87% at $1.16 per share, beating estimates of $1.15 a share.
Mylan is trading around $36 a share, and they are near their 52-week low of $33.60. A major reason for Mylan is trading near their 52-week low is because of recent controversy over their price hike on the EpiPen. Furthermore, Mylan has experienced further controversy with lawmakers questioning their Medicaid rebates for EpiPen. We have a full earnings preview here, and their average EPS surprise is 0.86%.
Bottom Line
How should investors play Mylan ahead of their earnings report? For insights on the best options trades, make sure you are subscribe to Live Trader to see Dave Bartosiak at 1:30 pm this afternoon.
Confidential from Zacks
Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>
Due to inactivity, you will be signed out in approximately:
Image: Bigstock
The Best Options Trade for Mylan (MYL) Earnings
On Wednesday, November 9th, Mylan will release its third quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.
Dave will look at Mylan’s past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Mylan ahead of earnings.
Mylan in Focus
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Mylan is expected to report earnings at $1.51 a share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 0.87% at $1.16 per share, beating estimates of $1.15 a share.
MYLAN NV Price, Consensus and EPS Surprise
MYLAN NV Price, Consensus and EPS Surprise | MYLAN NV Quote
Mylan is trading around $36 a share, and they are near their 52-week low of $33.60. A major reason for Mylan is trading near their 52-week low is because of recent controversy over their price hike on the EpiPen. Furthermore, Mylan has experienced further controversy with lawmakers questioning their Medicaid rebates for EpiPen. We have a full earnings preview here, and their average EPS surprise is 0.86%.
Bottom Line
How should investors play Mylan ahead of their earnings report? For insights on the best options trades, make sure you are subscribe to Live Trader to see Dave Bartosiak at 1:30 pm this afternoon.
Confidential from Zacks
Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>